## SEQUENCE LISTING

## RECEIVED

APR 0 5 2001

TECH CENTER 1600/2900

```
<110> Max-Delbrück-Centrum für Molekulare Medizin
```

<120> Tumor vaccines fdr muc1-positive carcinomas

<130> 107-027

<140> Ser.No. 09/606,910

<141> 2000-06-29

<150> DE 197 58 400.4

<151> 1997-12-30

<150> PCT/DE98/03819

<151> 1998-12-30

<160> 3

<170> PatentIn Ver. 2.1

<210> 1

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: designed synthetical glycopeptide

<400> 1

Ala His Gly Val Thr Ser Ala Pro Asp $\sqrt{10}$  Thr Arg Pro Ala Pro Gly Ser 1 5

Thr Ala Pro Pro Ala

Di

<210>/2

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: designed synthetical glycopeptide

<400> 2

His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr
1 10 15

Ala Pro Pro Ala

20

<210> 3

<21/1>7

<212> PRT

<220>
<221> BINDING
<222> (3)
<223> glycosylated

400> 3
Pro Asp Thr Arg Pro Ala Pro

1
5